Treatment of obstructive sleep apnoea improves metabolic conditions and prevents initiation of antiarrhythmic therapy in a patient with atrial fibrillation

Europace. 2014 Feb;16(2):245. doi: 10.1093/europace/eut233. Epub 2013 Aug 4.

Authors

Dominik Linz¹, Christian Ukena, Hans-Ruprecht Neuberger

Affiliation

¹ Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, 66421 Homburg/Saar, Germany.

PMID: 23918792
DOI: 10.1093/europace/eut233

No abstract available

Publication types

Case Reports

MeSH terms

Anti-Arrhythmia Agents / therapeutic use*
Atrial Fibrillation / diagnosis
Atrial Fibrillation / physiopathology
Atrial Fibrillation / prevention & control*
Atrial Premature Complexes / diagnosis
Atrial Premature Complexes / physiopathology
Atrial Premature Complexes / prevention & control*
Continuous Positive Airway Pressure
Electrocardiography, Ambulatory
Humans
Male
Metabolic Syndrome / diagnosis
Metabolic Syndrome / physiopathology
Metabolic Syndrome / therapy*
Middle Aged
Predictive Value of Tests
Recurrence
Risk Factors
Severity of Illness Index
Sleep Apnea, Obstructive / diagnosis
Sleep Apnea, Obstructive / physiopathology
Sleep Apnea, Obstructive / therapy*
Time Factors
Treatment Outcome

Substances

Anti-Arrhythmia Agents